Breakthrough Hepatitis B Drug Offers 'Functional Cure' for First Time

Hibsago Hepatitis B Shot Kept Virus Controlled in Nearly 1 in 5 Off Treatment but Carries Boxed Warning

FDA approved Hibsago for chronic hepatitis B with a boxed warning for liver reactions and low platelets. Here is who qualifies and what to monitor.

Breakthrough hepatitis B drug offers 'functional cure' for first time

For the first time, many people living with chronic hepatitis B may have a functional cure at hand. The US Food and Drug Administration (FDA) has approved the Hibsago (bepirovirsen) injection, which studies show can keep the disease under control without the need for endless doses of antiviral drugs.Continue ReadingCategory: Illnesses and conditions, Body and MindTags: FDA, Liver disease, Cancer, hepatitis-b, clinical trials

GSK Wins FDA Nod for Novel Hepatitis B Drug Offering a Potential Functional Cure

GSK’s Hibsago brings a new mechanism of action to chronic hepatitis B, targeting the genetic instructions the virus uses to make copies of itself and viral proteins. This drug was licensed from antisense oligonucleotide specialist Ionis Pharmaceuticals.

GSK picks up hep B drug approval

Today's biotech news includes Mark Cuban's pharmacy pursues rare disease, Inmatics' cancer therapy, and more

GSK, Ionis win US approval for first-of-its-kind hepatitis B drug

Hibsago is viewed as a potential “functional cure” for chronic infections and an important part of the British drugmaker’s goal of reaching £40 billion in annual revenue by 2031.

GSK wins FDA green light for chronic hep B treatment Hibsago

GSK's antisense-based drug for chronic hepatitis B virus (HBV) infection, Hibsago, has been approved in the US, its second major market after Japan.